Last patient enrolled in prospective arm of IVD trial
More than 2,250 prospective and retrospective samples enrolled in study
Data to be complemented with up to 500 additional contrived samples with [...]
- Interim data from prospective multicenter evaluation show 98% concordance with conventional microbiology
- Unyvero results on average available 24 hours earlier than in conventional microbiology, enabling rapid [...]
Additional preclinical data support potential of ARGX-111 in targeting tumor microenvironment
Breda, the Netherlands/Ghent, Belgium - June 03, 2016 - argenx (Euronext Brussels: ARGX), a clinical-stage biop [...]
Bispecific Cancer Antibody Pipeline Optimized by GlymaxX® Manufacturing Technology
BERLIN & UTRECHT, The Netherlands, June 01, 2016 (GLOBE NEWSWIRE) -- ProBioGen AG and Merus N.V. (Nasdaq:MRUS) today jointly ann [...]
Breda, the Netherlands / Ghent, Belgium - June 01, 2016 – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for th [...]
Our portfolio company Merus, based in Utrecht, the Netherlands, got listed today on NASDAQ, successfully raising $ 55 million in an initial public offering (IPO). LSP co-led the Series B financing of Merus in 2010 [...]
Basel, Switzerland – May, 17 2016 -- Nouscom announced today that it has closed a EUR 12 million Series A financing co-led by LSP and Versant Ventures. The funds will be used to support discovery and development of [...]
eTheRNA immunotherapies, the VUB spin-off that recently secured a EUR 24 million investment to continue the development of mRNA-based immunotherapies, has strengthened its management team with the appointment of Dr. [...]
UTRECHT, The Netherlands, May 04, 2016 (GLOBE NEWSWIRE) -- Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today that the first patient has been d [...]
Last patient enrolled in prospective arm of IVD trial
More than 2,250 prospective and retrospective samples enrolled in study
Data to be complemented with up to 500 additional contrived samples with [...]
- Interim data from prospective multicenter evaluation show 98% concordance with conventional microbiology
- Unyvero results on average available 24 hours earlier than in conventional microbiology, enabling rapid [...]
Additional preclinical data support potential of ARGX-111 in targeting tumor microenvironment
Breda, the Netherlands/Ghent, Belgium - June 03, 2016 - argenx (Euronext Brussels: ARGX), a clinical-stage biop [...]
Bispecific Cancer Antibody Pipeline Optimized by GlymaxX® Manufacturing Technology
BERLIN & UTRECHT, The Netherlands, June 01, 2016 (GLOBE NEWSWIRE) -- ProBioGen AG and Merus N.V. (Nasdaq:MRUS) today jointly ann [...]
Breda, the Netherlands / Ghent, Belgium - June 01, 2016 – argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for th [...]
Our portfolio company Merus, based in Utrecht, the Netherlands, got listed today on NASDAQ, successfully raising $ 55 million in an initial public offering (IPO). LSP co-led the Series B financing of Merus in 2010 [...]
Basel, Switzerland – May, 17 2016 -- Nouscom announced today that it has closed a EUR 12 million Series A financing co-led by LSP and Versant Ventures. The funds will be used to support discovery and development of [...]
eTheRNA immunotherapies, the VUB spin-off that recently secured a EUR 24 million investment to continue the development of mRNA-based immunotherapies, has strengthened its management team with the appointment of Dr. [...]
UTRECHT, The Netherlands, May 04, 2016 (GLOBE NEWSWIRE) -- Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today that the first patient has been d [...]
Follow us
